Literature DB >> 1761728

Optimal sampling theory and population modelling: application to determination of the influence of the microgravity environment on drug distribution and elimination.

G L Drusano1.   

Abstract

Newer mathematical techniques such as optimal sampling theory and NON-linear Mixed Effects Modelling (NONMEM) allow the determination of pharmacokinetics and pharmacodynamics in populations of individuals previously believed to be "too ill" or "too difficult to study." Optimal sampling determines the most information-rich times to sample the system, allowing robust parameter estimates to be determined from the minimal number of samples. NONMEM, by taking the population as the unit of analysis, allows even fragmentary patient data sets to contribute to population parameter estimates. Obviously, the microgravity environment presents extreme logistical difficulties to the performance of traditional pharmacokinetic and pharmacodynamic studies. Examples of the validation of these techniques are presented, which indicates their likely utility in the important task of determining the influence of the microgravity environment on drug distribution and elimination, even accounting for the limitations of support which will be faced in this circumstance.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1761728     DOI: 10.1002/j.1552-4604.1991.tb03657.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

1.  Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a nonparametric algorithm and optimal sampling strategy.

Authors:  A A Vinks; J W Mouton; D J Touw; H G Heijerman; M Danhof; W Bakker
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.

Authors:  M Tod; J M Rocchisani
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

3.  Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.

Authors:  S L Preston; G L Drusano; A L Berman; C L Fowler; A T Chow; B Dornseif; V Reichl; J Natarajan; F A Wong; M Corrado
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

4.  Optimal sampling schedule design for populations of patients.

Authors:  Vincent H Tam; Sandra L Preston; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

Review 5.  Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Authors:  Cornelia B Landersdorfer; Jürgen B Bulitta; Martina Kinzig; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

6.  Population pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections.

Authors:  S Payen; R Serreau; A Munck; Y Aujard; Y Aigrain; F Bressolle; E Jacqz-Aigrain
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

7.  Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patients.

Authors:  Patrick O Hanafin; Roger L Nation; Marc H Scheetz; Alexandre P Zavascki; Ana M Sandri; Andrea L Kwa; Benjamin P Z Cherng; Christine J Kubin; Michael T Yin; Jiping Wang; Jian Li; Keith S Kaye; Gauri G Rao
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-11-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.